Overview

Investigation of Flare and Remission in Subjects With Atopic Dermatitis

Status:
Withdrawn
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
The trial is an exploratory, single-centre, uncontrolled, open-label, interventional trial of up to 19 weeks' duration to investigate flare and remission in subjects with moderate-to-severe atopic dermatitis (AD) treated with cyclosporine A (CsA).
Phase:
Phase 4
Details
Lead Sponsor:
LEO Pharma
Treatments:
Cyclosporine
Cyclosporins